AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02463058 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise under hot and humid conditions protocol
Description: acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade \& 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously~experiment days (3 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (30 deg. centigrade \& 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously.
Study NCT00027573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00027573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Study NCT00027573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00027573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00027573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT04330079 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Lifestyle modification
Description: lifestyle modification (diet and exercise) for 6 months
Study NCT00027573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Study NCT01491321 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bee Venom Acupuncture Therapy
Description: Bee Venom 1:20,000 under BVA Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week
Study NCT01491321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loxoprofen
Description: 60 mg/Tab, pers os 1Tab tid, for 3 weeks
Study NCT00782353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANA598 200 mg bid or placebo
Description: ANA598 200 mg bid or placebo
Study NCT00782353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANA598 400 mg bid or placebo
Description: ANA598 400 mg bid or placebo
Study NCT00782353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANA598 800 mg bid or placebo
Description: ANA598 800 mg bid or placebo
Study NCT01491321 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Loxoprofen
Description: 60 mg/Tab, pers os 1Tab tid, for 3 weeks
Study NCT01491321 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline (0.9% NaCl) under NS Increment Protocol~Increment Protocol as~* 1st week : SC 0.2cc/day, 2days/week~* 2nd week : SC 0.4cc/day, 2days/week~* 3rd week : SC 0.8cc/day, 2days/week
Study NCT03734172 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sample collection
Description: Specimen collection
Study NCT01237509 — intervention group
Intervention type: DEVICE
Intervention: Hypo device
Study NCT00027573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study NCT01965015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of the V-Wave inter-atrial shunt
Description: Percutaneous implantation of the V-Wave shunt by right heart catheterization (RHC) approach
Study NCT00758225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone
Description: Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients > 45 kg: 900 mg/day (2 tablets 3 times a day)
Study NCT02911610 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: arthroscopy + volar plate
Description: surgery of wrist fractures with volar plate and added arthroscopy
Study NCT02911610 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Volar plate
Description: surgery of wrist fractures with volar plate
Study NCT00595127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (10mg/kg/day x 4days)
Study NCT00595127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine (30mg/m\^2/day x 5 days)
Study NCT00595127 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI)
Description: TBI (450 cGY in a single fraction)
Study NCT05647824 — intervention group
Intervention type: DEVICE
Intervention: Capillary Testing
Description: Testing Contour Fit BGMS with capillary blood
Study NCT05647824 — intervention group
Intervention type: DEVICE
Intervention: Alternative Site Testing (AST)
Description: Testing Contour Fit BGMS using blood from alternative site
Study NCT05647824 — intervention group
Intervention type: DEVICE
Intervention: Venous Testing
Description: Testing Contour Fit BGMS with venous blood
Study NCT01850199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart telemedicine remote monitoring for gestational diabetes
Description: Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.
Study NCT01850199 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual management
Description: Usual care will be provided, including face-to-face visits
Study NCT03228238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C and Vitamin E
Description: Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU
Study NCT03228238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statin
Description: Atorvastatin calcium 10mg
Study NCT03228238 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard medication for variant angina
Description: Calcium Channel blocker or NG
Study NCT03228238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard medication for variant angina
Description: Calcium Channel blocker or NG
Study NCT06360588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT06360588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06360588 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib
Description: Given IV
Study NCT06360588 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiologic Examination
Description: Undergo radiologic evaluation
Study NCT00451425 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: motivational intervention in pregnancy
Description: Motivational program including individualized counseling on diet and physical activity
Study NCT04072484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mild hypoxia
Description: The subject will breathe a gas mixture containing 15% oxygen instead of 21% oxygen.
Study NCT03826420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCF Supervision with Secure Confinement Sanctioning
Description: Parolees assigned to this group will, in the face of a violation, be given a sanction that involves secure confinement.
Study NCT03826420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCF Supervision with Work Release Sanctioning
Description: Parolees assigned to this group will, in the face of a violation, be given a sanction that involves work-release.
Study NCT03826420 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCF Supervision with GPS Supervision Sanctioning
Description: Parolees assigned to this group will, in the face of a violation, be given a sanction that involves GPS supervision.
Study NCT03678012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferumoxytol/Hydrogen peroxide
Description: 1.5% Ferumoxytol / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
Study NCT03678012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrogen Peroxide
Description: Sham Solution / 3% Hydrogen Peroxide (H2O2) 1:1 ratio. Each subject will use this product during one of three treatment periods in the crossover study design.
Study NCT03678012 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Water
Description: Sham solution (water; negative control). Each subject will use this product during one of three treatment periods in the crossover study design.
Study NCT01556490 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TheraSphere
Description: Yttrium 90 microspheres
Study NCT03245359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short-term ON-Q
Description: single port, select-a-flow pump connected to saphenous nerve block catheter until medication in initial balls are depleted (usually 2-4 days)
Study NCT03245359 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Short-term ON-Q
Description: single port, fixed flow pump connected to posterior knee catheter until medication in initial balls are depleted (usually 2-4 days)
Study NCT03245359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-term ON-Q
Description: Bupivacaine 0.125%
Study NCT03245359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long-term ON-Q
Description: single port, select-a-flow pump connected to saphenous nerve block catheter until day 7 post-operative
Study NCT03245359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Long-term ON-Q
Description: single port, fixed flow pump connected to posterior knee catheter until day 7 post-operative
Study NCT04011878 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined trabeculotomy trabeculectomy with mitomycin C
Description: Combined trabeculotomy trabeculectomy with mitomycin C with histopathological examination of the peripheral iris tissue specimen of all cases
Study NCT01061554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 oils from tri-glycerides
Description: Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
Study NCT01061554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 oils from tri-glycerides
Description: Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
Study NCT01061554 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 oils from marine phospholipids
Description: Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
Study NCT02289599 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2307 Matching Placebo
Study NCT03245359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-term ON-Q
Description: Bupivacaine 0.125%
Study NCT03741816 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indirect pulp capping
Description: Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
Study NCT03741816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indirect pulp capping
Description: Indirect pulp capping is a procedure in which a material is placed on a thin partition of remaining carious dentin that, if removed might expose the pulp.
Study NCT04303065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Oral
Description: It will be a short and descending course of oral dexamethasone: 4mg/6 hours (2 days); 4 mg/8 hours (2 days); 2 mg/6 hours (2 days); 2 mg/8 hours (2 days); 1 mg/8 hours (2 days); 1 mg/12 hours (2 days).
Study NCT04303065 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: The preparation and conditioning of the placebo capsules will be carried out following the standardized work procedures of the pharmaceutical laboratory and its quality controls, previously authorized by the Agencia Española del Medicamento (AEMPS).
Study NCT04698668 — intervention group
Intervention type: DEVICE
Intervention: fusion imaging
Description: To drain a pancreatic fluid collection through the assitance of the CT-scan image that is superimposed on the radiological field
Study NCT04076982 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mung bean protein
Description: Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
Study NCT04076982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control biscuit
Description: Participants were instructed to consume the test foods in the morning hours and to keep a record of the days the foods were consumed on a study calendar which was returned to investigators at the final visit and used to track protocol adherence.
Study NCT02492152 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study group
Description: Dianatal
Study NCT00261859 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BNI
Description: behavioral- brief intervention
Study NCT03381898 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Exercise, speech therapy, medication management
Description: Telehealth exercise once per week, speech therapy 4 times per week, medication management once per week
Study NCT02989922 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SHR-1210
Description: SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
Study NCT00711087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BOTOX-A
Description: Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90
Study NCT00711087 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: Group 2-sham saline injections on both Day 0 and Day 90.
Study NCT01753999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPAP
Description: Use of the REMstar Auto A-Flex in standard CPAP therapy mode
Study NCT01753999 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP - Flex
Description: Use of Philips Respironics REMstar Auto A-Flex in C-Flex mode
Study NCT04762667 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: reverse shoulder arthroplasty
Description: In our work, all patients are performs MSCT of the shoulder joint. The construction of a 3D model is carried out using the obtained data. Taking into account the individual features of the bone structure of the shoulder joint, images of the pilot wire guides, fixing screws and a resection template for the humerus are created. Holes for fixing spokes for the planned structures are also calculated.~Using a 3D printer, models of guides and a resection template are printed. During the reverse shoulder arthropalsty, instead of a standard guide, patient-specific instrumentation are used.~In the early postoperative period, all patients are performs MSCT of the shoulder joint. The obtained data are compared with the results of MSCT of the shoulder joints of patients previously operated on using the standard technique.
Study NCT04762667 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: reverse shoulder arthroplasty
Description: In our work, all patients are performs MSCT of the shoulder joint. The construction of a 3D model is carried out using the obtained data. Taking into account the individual features of the bone structure of the shoulder joint, images of the pilot wire guides, fixing screws and a resection template for the humerus are created. Holes for fixing spokes for the planned structures are also calculated.~Using a 3D printer, models of guides and a resection template are printed. During the reverse shoulder arthropalsty, instead of a standard guide, patient-specific instrumentation are used.~In the early postoperative period, all patients are performs MSCT of the shoulder joint. The obtained data are compared with the results of MSCT of the shoulder joints of patients previously operated on using the standard technique.
Study NCT03203473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells
Study NCT03203473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs
Study NCT04291560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stretching Exercise Intervention
Description: Sequential static stretching of the large skeletal muscle group 5 days per week. Each skeletal group is stretched for 20 seconds for 3 repetitions.
Study NCT02426502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion to Advagraf
Description: Prograf treated patients will convert to Advagraf using a 1: 1 conversion for a period of one week. The dose will then be titrated based on tacrolimus trough levels obtained 7 days after conversion. Cyclosporine (Neoral) treated patients will initiate Advagraf 0.075 mg/kg/day, 24 hours after their last cyclosporine dose. Participants will be provided with Advagraf and instructed how to start this new medication
Study NCT02426502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conversion of non-immunosuppressant drugs to once daily
Description: * Conversion of anti-hypertensive medications: converted to once daily alternatives with the goal of maintaining blood pressure at the same or lower level prior to conversion.~* Conversion of all other medications: changed to once daily formulations of the same medication or a once daily alternative.
Study NCT02426502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conversion to once daily MPA
Description: * Conversion to once daily MPA: Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.~* Conversion to once daily Myfortic: Patients prescribed proton pump inhibitors (PPIs) and MMF will be switched to equivalent dose Myfortic for a period of one month prior to conversion to once daily MPA.~* Patients taking azathioprine will be maintained on the same dose.~* Patients will be maintained on the same prednisone dose.
Study NCT01334229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg/d for 6 weeks
Study NCT01334229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 6 weeks
Study NCT01028963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules once daily
Study NCT01028963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pioglitazone
Description: pioglitazone 30 mg tablet once daily
Study NCT01028963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: CCX140-B capsules once daily (Group C)
Study NCT01028963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: CCX140-B capsules once daily (Group D)
Study NCT01525329 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-Fluorouracil
Description: All patients will receive one cream, 5-Fluorouracil, and will be instructed to apply the cream according to the randomization schema to AKs on either the right or left side of the face/scalp once a day for 6 days prior to PDT. A baseline measurement of the tumor's ability to produce PpIX will be done by applying methyl-aminolevulinic acid (Metvixia® topical cream) to the selected AKs and using the Aurora© dosimeter. Prior to Metvixia, and again 3 hours after application, surface measurements of the PpIX fluorescence will be taken. Then, the two largest precancer lesions (one on the left side, one on the right side) will be biopsied under local anesthesia, followed by red light PDT (lasting \~8 minutes). The biopsy sites will be shielded from the light with a circular spot bandage.
Study NCT01525329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: All patients will receive one cream, 5-Fluorouracil, and will be instructed to apply the cream according to the randomization schema to AKs on either the right or left side of the face/scalp once a day for 6 days prior to PDT. A baseline measurement of the tumor's ability to produce PpIX will be done by applying methyl-aminolevulinic acid (Metvixia® topical cream) to the selected AKs and using the Aurora© dosimeter. Prior to Metvixia, and again 3 hours after application, surface measurements of the PpIX fluorescence will be taken. Then, the two largest precancer lesions (one on the left side, one on the right side) will be biopsied under local anesthesia, followed by red light PDT (lasting \~8 minutes). The biopsy sites will be shielded from the light with a circular spot bandage.
Study NCT00185289 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EV/DNG (Qlaira, BAY86-5027, SH T00658K)
Description: per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
Study NCT01495650 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tailored program of PA and nutritional counseling
Description: Patients receive tailored program of physical exercises and nutritional counseling during the course of adjuvant treatments (CT followed by RT, 27 weeks).
Study NCT04032405 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF+CTG+i-prf
Description: combined connective tissue graft (CTG) and injectable platelet rich fibrin (i-prf) with coronally advanced flap (CAF)